A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer

Claus Høgdall; Eric T Fung; Ib J Christensen; Lotte Nedergaard; Svend A Engelholm; Anette L Petri; Signe Risum; Lene Lundvall; Christine Yip; Anette T Pedersen; Dorthe Hartwell; Lee Lomas; Estrid V S Høgdall

doi:10.1016/j.ygyno.2011.07.018

A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer

Claus Høgdall, Eric T Fung, Ib J Christensen, Lotte Nedergaard, Svend A Engelholm, Anette L Petri, Signe Risum, Lene Lundvall, Christine Yip, Anette T Pedersen, Dorthe Hartwell, Lee Lomas, Estrid V S Høgdall

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

25 Citationer (Scopus)

Abstract

Previous reports have shown that the proteomic markers apolipoprotein A1, hepcidin, transferrin, inter-alpha trypsin IV internal fragment, transthyretin, connective-tissue activating protein 3 and beta-2 microglobulin may discriminate between a benign pelvic mass and ovarian cancer (OC). The aim was to determine if these serum proteomic biomarkers alone as well as in combination with age and serum CA125, could be helpful in triage of women with a pelvic mass.

Originalsprog	Engelsk
Tidsskrift	Gynecologic Oncology
Vol/bind	123
Udgave nummer	2
Sider (fra-til)	308-13
Antal sider	6
ISSN	0090-8258
DOI	https://doi.org/10.1016/j.ygyno.2011.07.018
Status	Udgivet - 2011

Adgang til dokumentet

10.1016/j.ygyno.2011.07.018

Citationsformater

Høgdall, C., Fung, E. T., Christensen, I. J., Nedergaard, L., Engelholm, S. A., Petri, A. L., Risum, S., Lundvall, L., Yip, C., Pedersen, A. T., Hartwell, D., Lomas, L., & Høgdall, E. V. S. (2011). A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecologic Oncology, 123(2), 308-13. https://doi.org/10.1016/j.ygyno.2011.07.018

@article{cf22dde7f10445d4b9d24229a5c1bd91,

title = "A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer",

abstract = "Previous reports have shown that the proteomic markers apolipoprotein A1, hepcidin, transferrin, inter-alpha trypsin IV internal fragment, transthyretin, connective-tissue activating protein 3 and beta-2 microglobulin may discriminate between a benign pelvic mass and ovarian cancer (OC). The aim was to determine if these serum proteomic biomarkers alone as well as in combination with age and serum CA125, could be helpful in triage of women with a pelvic mass.",

author = "Claus H{\o}gdall and Fung, {Eric T} and Christensen, {Ib J} and Lotte Nedergaard and Engelholm, {Svend A} and Petri, {Anette L} and Signe Risum and Lene Lundvall and Christine Yip and Pedersen, {Anette T} and Dorthe Hartwell and Lee Lomas and H{\o}gdall, {Estrid V S}",

year = "2011",

doi = "10.1016/j.ygyno.2011.07.018",

language = "English",

volume = "123",

pages = "308--13",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press",

number = "2",

}

TY - JOUR

T1 - A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer

AU - Høgdall, Claus

AU - Fung, Eric T

AU - Christensen, Ib J

AU - Nedergaard, Lotte

AU - Engelholm, Svend A

AU - Petri, Anette L

AU - Risum, Signe

AU - Lundvall, Lene

AU - Yip, Christine

AU - Pedersen, Anette T

AU - Hartwell, Dorthe

AU - Lomas, Lee

AU - Høgdall, Estrid V S

PY - 2011

Y1 - 2011

N2 - Previous reports have shown that the proteomic markers apolipoprotein A1, hepcidin, transferrin, inter-alpha trypsin IV internal fragment, transthyretin, connective-tissue activating protein 3 and beta-2 microglobulin may discriminate between a benign pelvic mass and ovarian cancer (OC). The aim was to determine if these serum proteomic biomarkers alone as well as in combination with age and serum CA125, could be helpful in triage of women with a pelvic mass.

AB - Previous reports have shown that the proteomic markers apolipoprotein A1, hepcidin, transferrin, inter-alpha trypsin IV internal fragment, transthyretin, connective-tissue activating protein 3 and beta-2 microglobulin may discriminate between a benign pelvic mass and ovarian cancer (OC). The aim was to determine if these serum proteomic biomarkers alone as well as in combination with age and serum CA125, could be helpful in triage of women with a pelvic mass.

U2 - 10.1016/j.ygyno.2011.07.018

DO - 10.1016/j.ygyno.2011.07.018

M3 - Journal article

SN - 0090-8258

VL - 123

SP - 308

EP - 313

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 2

ER -